Sensorion SA

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Show More...

  • Website https://www.sensorion.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.40 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -0.3 -0.5 -0.91 -1.19 -1.09 -1.34 -1.08 -0.65 -0.65
    Dividends EUR
    Payout Ratio % *
    Shares Mil 3.0 3.0 3.0 4.0 7.0 7.0 11.0 19.0 19.0
    Book Value Per Share * EUR 1.01 1.54 0.62 0.77 0.06 0.23
    Free Cash Flow Per Share * EUR -0.74 -1.27 -1.17 -0.74 -0.69
    Return on Assets % -260.7 -217.94 -185.34 -45.65 -62.45 -70.49 -119.2 -50.86 -50.86
    Financial Leverage (Average) 14.5 1.27 1.36 1.53 2.7 2.88 2.88
    Return on Equity % -67.49 -81.68 -101.41 -227.27 -144.61 -144.61
    Return on Invested Capital % -53.97 -75.59 -77.57 -217.19 -56.27 -56.27
    Interest Coverage -179.9 -86.66 -8.16 -8.16
    Current Ratio 1.91 0.46 1.04 16.32 4.29 5.04 1.91 1.59 1.59
    Quick Ratio 0.74 0.2 0.51 14.84 3.46 3.88 0.63 1.33 1.33
    Debt/Equity 0.2 0.25 0.05 0.05